Seroatlas · Human Serome Atlas

CEACAM3

Cell adhesion molecule CEACAM3

Also known as: CD66d, CEAM3_HUMAN, CGM1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P40198
Gene: CEACAM3
Ensembl: ENSG00000170956
Chromosome: 19
Canonical length: 252 aa
Protein class: CD markers, Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a member of the family of carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), which are used by several bacterial pathogens to bind and invade host cells. The encoded transmembrane protein directs phagocytosis of several bacterial species that is dependent on the small GTPase Rac. It is thought to serve an important role in controlling human-specific pathogens by the innate immune system. Alternatively spliced transcript variants have been described. [provided by RefSeq, Mar 2013]

Canonical amino-acid sequenceUniProt

252 residues, UniProt reviewed canonical sequence.

>P40198|CEACAM3
     1  MGPPSASPHR ECIPWQGLLL TASLLNFWNP PTTAKLTIES MPLSVAEGKE VLLLVHNLPQ
    61  HLFGYSWYKG ERVDGNSLIV GYVIGTQQAT PGAAYSGRET IYTNASLLIQ NVTQNDIGFY
   121  TLQVIKSDLV NEEATGQFHV YQENAPGLPV GAVAGIVTGV LVGVALVAAL VCFLLLAKTG
   181  RTSIQRDLKE QQPQALAPGR GPSHSSAFSM SPLSTAQAPL PNPRTAASIY EELLKHDTNI
   241  YCRMDHKAEV AS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CEACAM3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.49
Highest tissue expression: 42 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 42 nTPM
spleen: 5.8 nTPM
appendix: 4.8 nTPM
lung: 2 nTPM
tongue: 1.2 nTPM
urinary bladder: 0.9 nTPM

Single-cell type

neutrophils: 226 nCPM
neutrophil progenitors: 138 nCPM
esophageal apical cells: 14 nCPM
kupffer cells: 7.2 nCPM
megakaryocytes: 6.2 nCPM
colonocytes: 5.7 nCPM

Immune cell

neutrophil: 291 nTPM
non-classical monocyte: 46 nTPM
intermediate monocyte: 19 nTPM
myeloid DC: 4.3 nTPM
classical monocyte: 4.2 nTPM
total PBMC: 3.2 nTPM

Brain region

cerebral cortex: 1.9 nTPM
choroid plexus: 0.7 nTPM
pons: 0.7 nTPM
basal ganglia: 0.1 nTPM
thalamus: 0.1 nTPM
amygdala: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.52
gnomAD pLI: 0
gnomAD missense Z: -0.08
DepMap mean gene effect: 0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

protein tyrosine kinase binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CEACAM3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CEACAM3 as an antibody target. Whether an autoantibody or antibody against CEACAM3 could matter depends on whether native CEACAM3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CEACAM3 is annotated at the cell surface, where native CEACAM3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CEACAM3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...